Somatostatin receptor expression and patients’ response to targeted medical treatment in pituitary tumors: evidences and controversies

F. Gatto, M. Arvigo, D. Ferone

Research output: Contribution to journalReview articlepeer-review


Background: Somatostatin receptors (SSTs) are widely co-expressed in pituitary tumors. SST2 and SST5 are the most represented SST subtypes. First-generation somatostatin receptor ligands (SRLs) mainly target SST2, while pasireotide, a multi-receptor ligand, shows high binding affinity for both SST5 and SST2. Therefore, SRLs are routinely used as medical treatment for GH-, TSH-, and ACTH-secreting pituitary tumors. Methods: Critical revision of literature data correlating SST expression with patients’ response to SRLs. Results: SST2 expression in somatroph tumors directly correlates with GH and IGF-1 decrease after first-generation SRL treatment. SST2 immunohistochemistry represents a valuable tool to predict biochemical response to first-generation SRLs in acromegalic patients. Pasireotide seems to exert its biological effects via SST2 in unselected patients. However, in those subjects resistant to first-generation SRLs, harbouring tumors with negligible SST2 expression, pasireotide can act throughout SST5. More than somatotroph tumors, TSH-omas represent the paradigm of tumors showing a satisfactory response to SRLs. This is probably due to the high SST2 expression observed in nearly 100% of cases, as well as to the balanced amount of SST5. In corticotroph tumors, pasireotide mainly act via SST5, although there is a need for translational studies correlating its efficacy with SST expression in this peculiar tumor histotype. Conclusions: The assumption “more target receptor, more drug efficacy” is not straightforward for SRLs. The complex pathophysiology of SSTs, and the technical challenges faced to translate research findings into clinical practice, still need our full commitment to make receptor evaluation a worthwhile procedure for individualizing treatment decisions.

Original languageEnglish
JournalJournal of Endocrinological Investigation
Publication statusAccepted/In press - 2020


  • Acromegaly
  • Cushing’s disease
  • Octreotide
  • Pasireotide
  • Pituitary tumors
  • Somatostatin receptor ligands
  • Somatostatin receptors

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Somatostatin receptor expression and patients’ response to targeted medical treatment in pituitary tumors: evidences and controversies'. Together they form a unique fingerprint.

Cite this